

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

TRIM23 RABBIT PAB

Cat.#: S221019

Product Name: Anti-TRIM23 Rabbit Polyclonal Antibody

Synonyms: ARD1; ARFD1; RNF46

UNIPROT ID: P36406 (Gene Accession - NP_001647)

Background: The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. This protein is also a member of the ADP ribosylation factor family of guanine nucleotide-binding family of proteins. Its carboxy terminus contains an ADP-ribosylation factor domain and a guanine nucleotide binding site, while the amino terminus contains a GTPase activating protein domain which acts on the guanine nucleotide binding site. The protein localizes to lysosomes and the Golgi apparatus. It plays a role in the formation of intracellular transport vesicles, their movement from one compartment to another, and phopholipase D activation. Three alternatively spliced transcript variants for this gene have been described.

Immunogen: Synthetic peptide of human TRIM23

Applications: ELISA, IHC

Recommended Dilutions: IHC: 20-100; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal


Isotype: Immunogen-specific rabbit IgG **Purification:** Antigen affinity purification **Species Reactivity:** Human, Mouse, Rat

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40%


glycerol

Research Areas: Signal Transduction

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human esophagus cancer tissue using 221019(TRIM23 Antibody) at a dilution of 1/25(Nucleus).



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with the synthetic peptide and then with 221019(Anti-TRIM23 Antibody) at dilution 1/25.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010